Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2022-N-0117]
 AGENCY: Food and Drug Administration, Health and Human Services (HHS).
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Fax written comments on the collection of information by August 5, 2022.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to 
                        *oira_submission@omb.eop.gov.*
                         All comments should be identified with the OMB control number 0910-0595. Also include the FDA docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-45, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, 
                        *PRAStaff@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Emergency Use Authorization of Medical Products OMB Control Number 0910-0595—Extension This information collection helps support implementation of Agency policies applicable to the authorization for medical products for use in emergencies under sections 564, 564A, and 564B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360bbb-3, 360bbb-3a, and 360bbb-3b). For more information regarding emergency use authorization (EUA), visit our website at 
                    *https://www.fda.gov/​
                        ( print page 40253)
                        emergency-preparedness-and-response/​mcm-legal-regulatory-and-policy-framework/​emergency-use-authorization.*
                     The FD&C Act permits the Commissioner of Food and Drugs (the Commissioner) to authorize the use of unapproved medical products, or unapproved uses of approved medical products, during an emergency declared under section 564 of the FD&C Act. The data to support issuance of an EUA must demonstrate that, based on the totality of the scientific evidence available to the Commissioner, including data from adequate and well-controlled clinical trials (if available), it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing a serious or life-threatening disease or condition (21 U.S.C. 360bbb-3(c)). Also under section 564 of the FD&C Act, the Commissioner may establish conditions on issuing an authorization that may be necessary or appropriate to protect the public health. These conditions can include: (1) requirements to disseminate or disclose information to healthcare providers or authorized dispensers and product recipients; (2) adverse event monitoring and reporting; (3) data collection and analysis; (4) specific recordkeeping and records access; (5) restrictions on product advertising, distribution, and administration; and (6) limitations on good manufacturing practice requirements. As governed by statute, some conditions are mandatory to the extent practicable for authorizations of unapproved products, and discretionary for authorizations of unapproved uses of approved products. Some conditions may apply to manufacturers of an EUA product, while other conditions may apply to any person who carries out an activity for which the authorization is issued. Sections 564A and 564B of the FD&C Act establish streamlined mechanisms intended to facilitate preparedness and response activities involving certain FDA approved products without requiring FDA to issue an EUA, and set forth emergency dispensing order and expiration date extension authority. The guidance document entitled, “Emergency Use Authorization of Medical Products and Related Authorities” (January 2017), available for download from our website at 
                    *https://www.fda.gov/​regulatory-information/​search-fda-guidance-documents/​emergency-use-authorization-medical-products-and-related-authorities,*
                     discusses FDA issuance of Emergency Use Authorizations (EUAs) under section 564 of the FD&C Act; implementation of the emergency use authorities set forth in section 564A of the FD&C Act; reliance on the governmental pre-positioning authority set forth in section 564B of the FD&C Act; and related FDA regulations. As discussed in the guidance document, the specific type and amount of data needed to support an EUA will vary depending on the nature of the declared emergency and the nature of the candidate product. The guidance document encourages early engagement with FDA, explains mechanisms for communication, and makes content and format recommendations on submitting information to the Agency. The guidance document also recommends that a request for consideration for an EUA include scientific evidence evaluating the product's safety and effectiveness, including the adverse event profile for diagnosis, treatment, or prevention of the serious or life-threatening disease or condition, as well as data and other information on safety, effectiveness, risks and benefits, and (to the extent available) alternatives. In the 
                    **Federal Register**
                     of March 3, 2022 (87 FR 12175), we published a 60-day notice requesting public comment on the proposed collection of information. Two comments were received. One comment communicated that the information collection has proven useful in expediting the availability of vaccines during the pandemic, and also suggested potential modifications. The second comment was not responsive to the information collection topics solicited in our 60-day notice. Neither comment offered alternative burden estimates. We estimate the burden of this collection of information as follows: Table 1—Estimated Annual Reporting Burden 1
Information collection activity
Number of 
                             respondents
Number of 
                             responses per respondent
Total annual 
                             responses
Average 
                             burden per  
                             response
Total hoursRequests for a substantive amendment to an existing EUA
2724
2
5448
45
245,160Pre-EUA submissions or amendments
2001
1
2001
34
68,034Submitting information required under conditions of authorization
36
3
108
8
864State and local public health authority submissions required under conditions of authorization for unapproved EUA product
1
1
1
2
2State and local public health authority requests for Emergency Dispensing Order
1
1
1
2
2State and local public health authority requests for expiration date extension
1
1
1
20
20Total


7560

314,0821
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 Although we have averaged burden across all respondents, we categorize reporting activity by the type of EUA-related submission: (1) those who file a request for FDA to issue an EUA and/or a substantive amendment to an EUA that has previously been issued; (2) those who submit a request for FDA to review information/data (
                    *i.e.,*
                     a pre-EUA package) for a candidate EUA product or a substantive amendment to an existing pre-EUA package for preparedness purposes; (3) those who must report on activities related to an unapproved EUA product (
                    *e.g.,*
                     administering product, disseminating information) who must report to FDA regarding such activity; (4) public health authorities (
                    *e.g.,*
                     State, local) who must report on certain activities (
                    *e.g.,*
                     administering product, disseminating information) related to an unapproved EUA, and public health authorities who submit an expiration date extension request for an approved product; (5) those who request an emergency dispensing order under section 564A; and (6) those who request 
                    ( print page 40254)
                    expiry dating extensions under section 564A of the FDC&C Act. We attribute greater burden to those requests for FDA to review pre-EUA packages submitted by product sponsors than burden we attribute to those submitted by Federal agencies (
                    *e.g.,*
                     Centers for Disease Control and Prevention, the Department of Defense), and have considered other factors that contribute to variability in burden for reporting, including the type of product and whether there is a previously reviewed pre-EUA package or investigational application. Table 2—Estimated Annual Recordkeeping Burden 1
Records associated with conditions of authorization
Number of 
                             recordkeepers
Number of 
                             records per  
                             recordkeeper
Total annual 
                             records
Average 
                             burden per  
                             recordkeeping
Total hoursEUA Holders
648
2
1,296
25
32,400State and local Public Health Authorities
1
1
1
3
3Total


1,297

32,4031
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 We provide a conservative estimate for respondent recordkeeping, recognizing that the Federal Government performs much of this activity in conjunction with submissions. We do not include burden for public health authorities who may need to submit emergency dispensing orders or expiration date extension requests, assuming covered entities already maintain these records for the products they stockpile. Table 3—Estimated Annual Third-Party Disclosure Burden 1
Information collection activity
Number of 
                             respondents
Number of 
                             disclosures per  
                             respondent
Total annual 
                             disclosures
Average 
                             burden per  
                             disclosure
Total hoursDissemination of required information by EUA Holder or Authorized Stakeholder
635
2
1270
5
63501
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 Our third-party disclosure estimate is based on the number of EUA holders and authorized stakeholders disseminating information, including fact sheets, advertising, and promotional materials. We have increased our burden estimate for the information collection to reflect the increase in submissions we have received over the last 3 years. Dated: June 23, 2022. Lauren K. Roth, Associate Commissioner for Policy.


[FR Doc. 2022-14347 Filed 7-5-22; 8:45 am] BILLING CODE 4164-01-P